Compare MVST & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | XBIT |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | 1908 | 87 |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.1M | 66.8M |
| IPO Year | 2019 | 2015 |
| Metric | MVST | XBIT |
|---|---|---|
| Price | $0.65 | $2.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 45.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $427,516,000.00 | N/A |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $17.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $0.56 | $2.09 |
| 52 Week High | $7.12 | $3.44 |
| Indicator | MVST | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 44.72 |
| Support Level | N/A | $2.19 |
| Resistance Level | $1.02 | $2.46 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 51.99 | 29.53 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.